0.025 (8.333%)
ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Weak
GARP
Very Weak
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Telephone
N/A
Address
Suite 12.01, Level 12 4-6 Bligh Street Sydney, New South Wales (NSW) 2000
Description
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.25 - 1.87
Trade Value (12mth)
AU$161,578.00
1 week
1.69%
1 month
0%
YTD
-77.38%
1 year
-82.35%
All time high
21.25
EPS 3 yr Growth
38.10%
EBITDA Margin
N/A
Operating Cashflow
-$76m
Free Cash Flow Return
-90.80%
ROIC
-82.80%
Interest Coverage
-437.40
Quick Ratio
1.70
Shares on Issue (Fully Dilluted)
220m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
5.18
| Date | Announcements |
|---|---|
|
05 September 25 |
S&P DJI Announces September 2025 Quarterly Rebalance
×
S&P DJI Announces September 2025 Quarterly Rebalance |
|
02 September 25 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
|
01 September 25 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
|
28 August 25 |
Final Share Purchase Plan Allotment
×
Final Share Purchase Plan Allotment |
|
27 August 25 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
|
27 August 25 |
Listed Options Top Holders Grouped & Holdings Range Report
×
Listed Options Top Holders Grouped & Holdings Range Report |
|
26 August 25 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
|
26 August 25 |
Corporate Governance Statement 2025 and Appendix 4G
×
Corporate Governance Statement 2025 and Appendix 4G |
|
20 August 25 |
EGM Presentation
×
EGM Presentation |
|
20 August 25 |
Results of Meeting
×
Results of Meeting |
|
18 August 25 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
|
12 August 25 |
Update - Proposed issue of securities - IMU
×
Update - Proposed issue of securities - IMU |
|
11 August 25 |
Share Purchase Plan Closing Date Extended
×
Share Purchase Plan Closing Date Extended |
|
04 August 25 |
79% Overall Response Rate With Two Further Partial Responses
×
79% Overall Response Rate With Two Further Partial Responses |
|
31 July 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
24 July 25 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
|
24 July 25 |
Cleansing Notice
×
Cleansing Notice |
|
23 July 25 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
|
23 July 25 |
Change of Director's Interest Notice x2
×
Change of Director's Interest Notice x2 |
|
21 July 25 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
|
18 July 25 |
Change of Director's Interest Notice x 3
×
Change of Director's Interest Notice x 3 |
|
16 July 25 |
Imugene Completes $22.5M Placement and c.$15M SPP
×
Imugene Completes $22.5M Placement and c.$15M SPP |
|
16 July 25 |
Proposed issue of securities - IMU
×
Proposed issue of securities - IMU |
|
16 July 25 |
Proposed issue of securities - IMU
×
Proposed issue of securities - IMU |
|
16 July 25 |
Imugene Capital Raising Presentation
×
Imugene Capital Raising Presentation |
|
16 July 25 |
Prospectus
×
Prospectus |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
